Chandrikha Chandrasekharan, MD is a nationally recognized medical oncologist whose clinical and research career is dedicated to the care of patients with neuroendocrine tumors (NETs), including rare and aggressive high‑grade neuroendocrine carcinomas. She practices within the multidisciplinary NET program at the University of Texas MD Anderson Cancer Center, where 70% of her clinical practice is devoted to NET patients, supported by years of focused experience and multiple NET‑related research publications.
Dr. Chandrasekharan’s research portfolio spans high‑grade neuroendocrine carcinoma, mixed neuroendocrine–non‑neuroendocrine neoplasms (MINENs), and circulating tumor cells, reflecting her commitment to advancing the understanding of complex and aggressive NET biology. Her subspecialty expertise includes lung, gastrointestinal, and pancreatic NETs, as well as management of liver metastases and palliative care considerations for advanced disease.
She is an active contributor to the scientific community, with involvement in studies exploring PRRT, radionuclide therapies, and evolving treatment strategies for GEP‑NETs, including the impact of peptide receptor radionuclide therapy on survival outcomes. As a frequent expert discussant in national peer‑exchange panels, Dr. Chandrasekharan contributes to shaping best practices for first‑line, second‑line, and high‑grade NET treatment decision‑making, helping clinicians navigate options ranging from somatostatin analogs to PRRT, targeted therapy, and multidisciplinary management approaches.
Her leadership extends across professional societies: she is a member of NANETS, ENETS, and the American Association for Cancer Research (AACR), and she has held leadership roles within NANETS, strengthening guidelines and advancing the strategic direction of NET research and education.
Dr. Chandrasekharan service on the NCAN Medical Advisory Board connects her to the NCAN community and she has appeared on the “NETs Get Real with NCAN” podcast to discuss multidisciplinary care, reinforcing her deep commitment to patient‑centered, expert‑led NET management.
Through her clinical practice, research leadership, and dedication to collaborative, compassionate care, Dr. Chandrikha Chandrasekharan continues to significantly influence the future of neuroendocrine oncology—especially for patients facing complex, high‑grade, and rapidly evolving forms of NET disease.